Last updated on November 2017

Metastatic Colorectal Cancer with wild-type KRAS tumors.

Brief description of study

Metastatic Colorectal Cancer with wild-type KRAS tumors.

Detailed Study Description

Objective response rate, duration of reponse, time to response, time to progression, disease control, overall survival, to evaluate changes in patient-reported outcomes.

Patient Inclusion Criteria:

  • 18 + years
  • Diagnosis of metastatic adenocarcinoma of the colon or rectum that cannot, in the opinon of the investigator, be cured by surgical resection at the time of randomization, wild-type KRAS expressing mCRC tumor, at least one uni-dimensionally measurable lesion

Patient Exclusion Criteria:

  • adiotherapy <14 days before randomization, evidence of central nervous system metastases, history of other invasive primary cancer

Clinical Study Identifier: TX820

Contact Investigators or Research Sites near you

Start Over

Dr. Tom Davis

Legacy Pharma Research
Bismarck, ND USA